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INFLUENCIA DE LA MASA CORPORAL Y DE LA
ADIPOSIDAD VISCERAL EN EL METABOLISMO
DE LA GLUCOSA EN MUJERES OBESAS CON EL
GENOTIPO PRO12PRO EN EL GENE PPARGAMMA2
Resumen
Introducción: El metabolismo de la glucosa puede estar
alterado en la obesidad y el genotipo del gene PPAR 2
puede influir en este variable. 
Objetivo: Evaluar la influencia de la masa corporal
(MC) y de la adiposidad visceral (AV) en el metabolismo
de la glucosa en mujeres con obesidad de grado 3 con el
genotipo Pro12Pro. 
Métodos: Se seleccionaron 25 mujeres con obesidad de
grado 3. Se formaron grupos de acuerdo con el índice de
masa corporal (IMC) [G1: 40-45 kg/m2 (n = 17), G2: > 45
kg/m2 (n = 8)]. Fueron hechas evaluaciones antropométri-
cas, de la glucemia y de la insulinemia (en ayunas, 60 y 120
minutos después de la comida rica en ácidos grasos poliin-
saturados). La resistencia a la insulina (RI) y sensibilidad
a la insulina (SI) fueron evaluados por el HOMA-IR y
QUICKI, respectivamente. 
Resultados: G2 tuvieron mayor índice de masa corpo-
ral y circunferencia de la cintura, en comparación con
G1, peor glucemia en ayunas, baja SI y alta RI. La glu-
cosa postprandial fue normal, pero hubo un pico de insu-
lina más alto una hora después de la comida en G2. 
Conclusión: El aumento de la MC y de la AV se asocia-
ron con peor metabolismo de la glucosa lo que sugiere
diferencias metabólicas entre obesos de grado 3 con el
genotipo Pro12Pro.
(Nutr Hosp. 2013;28:694-700)
DOI:10.3305/nh.2013.28.3.6372
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Abstract
Introduction: Glucose metabolism may be altered in
obesity and genotype for PPAR 2 can influence this varia -
ble. 
Objective: To evaluate the influence of body mass (BM)
and visceral adiposity (VA) in glucose metabolism in
morbid obese women with Pro12Pro genotype. 
Methods: Were selected 25 morbidly obese women.
Groups were formed according to body mass index (BMI)
[G1: 40-45 kg/m2 (n = 17); G2: > 45 kg/m2 (n = 8)]. Anthro-
pometric, glycemia and insulinemia assessments (fasting,
60 and 120 minutes after high polyunsaturated fatty acids
meal) were carried out. The insulin resistance (IR) and
insulin sensitivity (IS) were assessed by HOMA-IR and
QUICKI respectively. 
Results: G2 had higher BMI and waist circumference,
compared to G1, impaired fasting glucose, low IS and
higher IR. The postprandial glucose was normal, but
there was a higher insulin peak one hour after the meal in
G2. 
Conclusion: Increased BM and VA were associated
with worse glucose metabolism suggesting metabolic
differences between morbid obese with Pro12Pro geno-
type.
(Nutr Hosp. 2013;28:694-700)
DOI:10.3305/nh.2013.28.3.6372
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Abreviattions
BM: Body mass.
BMI: Body mass index.
bp: Base pairs.
C: Cytosine.
FURJ: Federal University of Rio de Janeiro.
G: Guanine.
HOMA-IR: Homeostasis Model Assessment-Insulin
Resistance.
IR: Insulin resistance.
IS: Insulin sensitivity.
MUFA: Monounsaturated fatty acids.
PCR-RFLP: Polymerase chain reaction-restriction
fragment-length polymorphism.
PPAR: Peroxisome proliferator-activated receptor.
PPARγ2: Peroxisome proliferator-activated receptor
isoform gamma 2.
PPRE: Peroxisome proliferator response element.
PUFA: Polyunsaturated fatty acids.
QUICKI: Quantitative Insulin Sensitivity Check Index.
SFA: Saturated fatty acids.
TEE: Total energy expenditure.
TZDs: Thiazolidinediones.
VA: Visceral adiposity.
WC: Waist circumference.
Introduction
Obesity is considered one of the most serious public
health problems throughout the world and results in
overload on health services with an increasing demand
for the treatment of other chronic diseases such as type
2 diabetes mellitus and cardiovascular disease.1 It is a
complex disease of multifactorial origin, with a strong
influence from hereditary and environmental factors.2
Although it has polygenic characteristics, studies
have emphasized the significant contribution of the
adipogenic transcription factor, peroxisome prolife-
rator-activated receptor (PPAR) isoform γ2 (PPARγ2)
in lipogenesis.2,3,4
The PPARs belong to a superfamily of nuclear
hormone receptors,5 constituting a subfamily of three
isoforms: PPARα, PPARγ and PPARβ/δ, which perform
essential functions in regulating the lipid metabolism.6,7
The PPARγ is presented in three subtypes (γ1, γ2 and γ3),
which are expressed in different tissues.7 The expression
of PPARγ2 occurs mainly in adipose tissue6,8, being
related to adipogenesis3, 6 and insulin sensitivity (IS).9,10
These transcription factors require activation from
natural ligands to act on target genes, which include
long-chain polyunsaturated fatty acids (PUFA),
derived from oxidized lipids and eicosanoids; or
synthetics, which include lipid-lowering and antidia-
betic drugs, such as thiazolidinediones (TZDs), which
have a high affinity for PPARγ.5,7
Genetic variants of PPARγ2 have been identified,
among which, Pro12Ala polymorphism, which is char-
acterized by the replacement of cytosine (C) to guanine
(G) in codon 12, with substitution of proline for alanine
in the polypeptide sequence (Pro12Ala and Ala12Ala).11
Studies are being conducted to elucidate the effects of
the wild-type genotype (Pro12Pro) and of the Ala variant
allele in the PPARγ2 gene, however, there is still no
consensus on the results.3,9,12 It is suggested that in the
presence of the Pro12 homozygous genotype, the activa-
tion of the gene by agonists is associated with the expres-
sion of enzymes involved in the capture and transport of
fatty acids, resulting in increased adipogenesis and
decreased concentrations of plasma free fatty acids. As a
result, there is less fat accumulation in liver and muscle
tissues, favoring IS in these tissues.13 However, in Ala
allele carriers, there is lower affinity of the PPARγ-ligand
complex with the peroxisome proliferator response
element (PPRE) of target genes12, which can result in less
effective stimulus, and consequently, lower accumula-
tion of adipose tissue.9 Moreover, the relationship of this
polymorphism with IS remains controversial.3, 9,12
Insulin resistance (IR) is characterized by decreased
effectiveness of insulin to stimulate glucose uptake in
skeletal muscle and in adipose tissue.14 This morbidity
predisposes individuals to several chronic diseases,
including hypertension, type 2 diabetes mellitus,
dyslipidemia, ischemic heart disease, as well as
providing generalized atherogenic activity. Among the
etiologic factors for IR, in addition to previously
reported genetic factors, there is the excess of body fat,
especially visceral fat deposition.1
Obese people with less visceral adipose tissue were
found to have normal glucose tolerance when compared
to lean controls. Obese people with a high accumulation
of visceral adipose tissue, however, showed an increase
in their glycemic response to an oral glucose load which
was measurably higher than in obese people with less
visceral adipose tissue or in nonobese controls. Major
differences were also noted in the plasma insulin
response to the oral glucose load. These comparisons
show that viscerally obese people represent a subgroup of
obese patients with the highest glycemic and insulinemic
responses to an oral glucose challenge and that they are at
the highest risk of developing type 2 diabetes mellitus.15
Our aim was to evaluate the influence of body mass
and visceral adiposity on glucose metabolism in fasting
and postprandial glucose in morbidly obese women
with genotype Pro12Pro in PPARγ2, considering the
relationship of obesity with other chronic diseases
associated with IR and the role of PPARγ2 gene in
adipogenesis and IS.
Materials and methods
Casuistry
We conducted a cross-sectional study of non-
randomized and non-controlled intervention with 25
morbidly obese adult women (22-48 years old).
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The study was approved by the Research Ethics
Committee of the University Hospital Clementino
Fraga Filho, of Federal University of Rio de Janeiro
(FURJ) (research protocol N. 116/05). All volunteers
signed the consent form before starting the search, as
established by Resolution nº 196/96 of the National
Health Council.
The inclusion criteria considered were: adult women
with a family history of obesity, lack of menopause,
and BMI equal to or greater than 40 kg/m2.16
The study excluded women in situations of smoking,
presence of cardiovascular diseases, chronic kidney
disease, diabetes mellitus and/or other chronic diseases,
infectious diseases, pregnant women, nursing, users of
lipid-lowering, hypoglycemic agents, diuretics, antide-
pressants, antihypertensives, and drugs supplements
and/or herbal remedies for weight loss, dieting for
weight loss in the last four weeks, or weight loss
greater than 3 kg in the last month.
Study design
We assessed the usual dietary intake in order to elim-
inate the influence of this variable in the parameters
studied. Dietary intake was estimated using dietary
records for three days, two days being typical and one
atypical. The analysis of the chemical composition of
the diets was performed using the Food Processor soft-
ware version 12 (Esha Research, Salem, USA, 1984),
after the adjustment for the typical Brazilian diet.
In the clinical trial, the volunteers were presented to
the Laboratory of Clinical Analysis of Pharmacy
College/FURJ at 7am after an overnight fast of 12
hours for the first blood sample for the biochemical
(total cholesterol and fractions, triglycerides, glucose
and insulin) and molecular (PPARγ2 genotype) assess-
ments. The anthropometric assessment was performed
immediately after.
A high n-6 PUFA meal was administered orally.
After one and two hours, blood samples were collected
to assess glucose and insulin concentrations.
The volunteers were divided into two groups
according to BMI, with G1 composed of women with
BMI between 40 and 45 kg/m2 (n = 17) and G2
composed of women with a BMI equal to or greater
than 45 kg/m2 (n = 8).
Biochemical measurements
Lipemia and glycemia were carried out at Labora-
tory of Clinical Analysis of Pharmacy College/FURJ.
For total cholesterol, HDL-cholesterol and triglyc-
erides measurements the commercial kits CHOLES-
TEROL Liquiform (Labtest Diagnostica SA, Brazil),
HDL CHOLESTEROL (Labtest Diagnostica SA,
Brazil) and triglycerides Liquiform (Labtest Diagnos-
tica SA, Brazil) were used, respectively. 
LDL-cholesterol and VLDL-cholesterol concentra-
tions were determined using the Friedewald equation.17
The reference values used for triglycerides, total
cholesterol, HDL-cholesterol and LDL-cholesterol
levels were < 150 mg/dL, < 200 mg/dL, > 60 mg/dL
and < 130 mg/dL, respectively.18
The determination of plasma glucose was performed
using the commercial kit GLUCOSE PAP Liquiform
(Labtest Diagnostica SA, Brazil). The reference values
for fasting plasma glucose followed the recommenda-
tions of the American Diabetes Association (ADA),
with appropriate values of fasting plasma glucose
being below 100 mg/dL.19
Analysis of serum insulin was performed using the
commercial kit COAT-A-Count® (Diagnostic Products
Corporation®, USA). Normal insulinemia and hyperin-
sulinemia were considered in volunteers with fasting
insulin < 9 µU/mL and > 9 µU/mL, respectively.20
Insulin resistance (IR) was estimated by calculating
HOMA-IR (Homeostasis Model Assessment) according
to Matthews et al.21 IR values were considered as
HOMA-IR ≥ 2.71.22
The QUICKI (Quantitative Insulin Sensitivity
Check Index) calculation was used to evaluate IS, as
proposed by Katz et al.23 QUICKI values above 0.33
were considered adequate.24
Anthropometry assessment 
Body weight and height were used to calculate BMI
and to estimate the total energy expenditure (TEE), and
consequently the total energy of the test meal. Body
weight was assessed using digital platform scale (Fili-
zola®) with an accuracy of 100 g and maximum
capacity of 150 kg, and height was measured with the
stadiometer of the same equipment with a scale of 0.1
cm. The volunteers were weighed with as little clothing
as possible and barefoot.25
The WC was measured at the midpoint between the
lower margin of the least palpable rib and the top of the
iliac crest, using a stretch-resistant tape.16
Genotyping PPARγ2
Molecular analyses were performed in the Labora-
tory of Molecular Biology of Cancer, of Federal
University of Rio de Janeiro. 
Genomic DNA was extracted from samples of
whole blood using a commercial kit (MasterPureTM
Genomic DNA Purification Kit, Epicentre®, Biotech-
nologies) and stored at -20° C until the subsequent step.
Determination of the Pro12Pro genotype was performed
using the polymerase chain reaction-restriction frag-
ment-length polymorphism (PCR-RFLP) method as
previously described26, according the sequences avail-
able in the Gen Bank DNA AB005520.27
The sequences of PCR primers were: 5’-GCC AAT
TCA AGC CCA GTC-3 ‘and 5’-GCC ATG TTT GCA
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GAC AGT GTA TCA GTG AAG GAA TCG CTT
TCC G- 3’. The cycling conditions were as follows: an
initial denaturation at 95º C for 5 minutes, followed by
35 cycles of denaturing at 95º C for 30 seconds,
annealing at 59º C for 30 seconds and extension at 72º
C for 30 seconds. The final extension was continued at
72º C for 10 minutes and cooling to 4º C. The generated
fragment was 267 bp (base pairs). 
After enzymatic digestion of the PCR products
(60ºC for 180 minutes) by Bst UI restriction endonu-
clease (New England Biolabs, Inc.), were generated
fragments of 267 bp indicating the presence of wild-
type homozygous genotype (Pro12Pro).26
Dietetic intervention
The TEE of each volunteer was estimated according to
FAO/WHO28 and the energy value of the meal was equiv-
alent to a breakfast (15-20% of the TEE), with normal
distribution of macronutrients (carbohydrates, proteins
and lipids), containing 15% of PUFA (a mean of 88.6%
and 11.4% of n-3 and n-6 PUFA, respectively), 10% of
monounsaturated fatty acids (MUFA) and less than 10%
of the saturated fatty acids (SFA). Calculations were
based on recommendations for normal individuals.18
The meal consisted of carrot cake without frosting,
toast, ricotta cheese plus soybean oil and skimmed
milk with the following characteristics: 511.2 ± 50.4
kcal, being 50.0 ± 0.6% carbohydrates, 19.0 ± 1.7%
proteins, 35.1 ± 0.5% lipids, 14.6 ± 0.5% PUFA, 9.3 ±
0.2% MUFA, 9.2 ± 0.4% of SFA and 5,485.9 ± 871.4
IU of vitamin A.
The analysis of the chemical composition of the
meals was conducted in Food Processor program
version 12 (Esha Research, Salem, USA, 1984).
Statistical analysis
Was used SPSS 11.0 for statistical analysis, consid-
ering significant p < 0.05.
To check the distribution of continuous variables
(clinical1, anthropometric2 and biochemical3) was done
the test of Kolmogorov-Smirnov (1: age; 2: body
weight, BMI and WC, 3: serum insulin, plasma
glucose, triglycerides, total cholesterol and fractions
(HDL-cholesterol, LDL-cholesterol and VLDL-
cholesterol) and values of HOMA-IR and QUICK).
For the comparison between the means of the
groups, the basic statistics of location (mean) and
dispersion (standard deviation) were calculated.
Continuous variables presented normal distribution
and was used the parametric Student t test for the compar-
ison between groups. When the variance was less than 4,
we used the Student t test for equal variances; otherwise,
we applied the Student t test for different variances.
Results
Among women recruited, only 4% (n = 1) had the
genotype variant (Ala), and therefore was excluded
from the study.
The volunteers were divided into two groups
according to BMI, with G1 (BMI between 40 and 45
kg/m2) composed of 17 women (68%) and G2 (BMI >
45 kg/m2) of 8 women (32 %), both morbidly obese.
Energy and macronutrients intake no differ between
groups (p > 0.05), which shows homogeneity between
them (table I).
The anthropometric and biochemical characteristics
are presented in table II. 
Body weight, BMI and WC differ between groups (p
< 0.05). All volunteers showed excess visceral
adiposity, represented by WC above 80 cm.29
G1 had normal fasting glucose (< 100 mg/dL) and
G2 had impaired fasting glucose (101.6 ± 22.1 mg/
dL)19, with no difference between groups (p > 0.05). In
G1 and G2, respectively, 29.4% and 50% of women
had impaired fasting glucose, so this rise was more
frequent in G2.
All women had a fasting insulin above the normal
range (13.3 U/mL and 14.0 U/mL, G1 and G2, respec-
Table I
Usual dietary intake (energy and macronutrients) by groups
Variables
G1 (n = 17)3 G2 (n = 8)4
Mean SD1 Mean SD
p-value2
Energy (kcal) 2,234.27 748.79 1,928.77 726.76 0.35
Carbohydrates (%) 45.55 7.08 45.67 3.29 0.95
Protein (%) 18.12 3.95 17.88 3.77 0.89
Fat (%) 36.33 7.17 36.45 2.54 0.95
MUFA5 (%) 13.35 3.53 13.08 1.80 0.84
SFA6 (%) 12.20 3.27 13.62 2.59 0.29
PUFA7 (%) 6.80 2.04 6.58 2.15 0.81
1Standard deviation; 2Difference between groups were tested with t-student unpaired test at 5% probability; 3BMI between 40 and 45 kg/m2; 4BMI >
40 kg/m2; 5Monounsaturated fatty acids; 6Saturated fatty acids; 7Polyunsaturated fatty acids. 
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tively)20 and values of HOMA-IR greater than 2.71
indicating IR.22 G1 had normal IS (QUICKI = 0.34 ±
0.05) and G2 showed low IS (QUICKI = 0.32 ± 0.03),
however, there was no difference between groups (p >
0.05).
There was no difference in lipemia (p > 0.05)
between groups and both showed normal mean values
for triglycerides and LDL-cholesterol and low HDL-
cholesterol concentrations.18 In G1, total cholesterol
was close to normal range (201.1 ± 40.7 mg/dL). In G1
and G2, 47.1% (n = 8) and 37.5% (n = 3) of the women,
respectively, had values above the recommended, but
there was no difference between groups (p > 0.05). 
Figure 1 shows the variations in blood insulin and
glucose in G1 and G2, at fasting, one and two hours
after eating the test meal. In both groups, there was an
Table II
Anthropometric and biochemical variables (mean ± standard deviation) by groups
Variables
G1 (n = 17)3 G2 (n = 8)4
Mean SD1 Mean SD
p-value2
Age (years) 35.9 7.2 37.1 7.3 0.69
Weight (kg) 113.4 9.9 129.6 10.3 < 0.01*
BMI5 (kg/m2) 42.4 1.5 49.5 4.8 < 0.01*
WC6 (cm) 120.4 6.2 130.9 9.3 < 0.01*
Fasting glucose (mg/dL) 91.9 18.5 101.6 22.1 0.26
Glucose 1 h after diet (mg/dL) 106.6 31.8 104.5 30.0 0.88
Glucose 2 h after diet (mg/dL) 100.1 31.1 95.6 28.5 0.74
Fasting insulin (µU/mL) 13.3 7.5 14.0 5.2 0.82
Insulin 1 h after diet (µU/mL) 61.2 46.6 82.2 53.0 0.32
Insulin 2 h after diet (µU/mL) 45.5 22.0 46.2 28.9 0.95
HOMA-IR7 3.2 2.2 3.6 1.8 0.61
QUICKI8 0.34 0.05 0.32 0.03 0.30
Total cholesterol (mg/dL) 201.1 40.7 190.9 39.1 0.56
LDL-cholesterol (mg/dL) 128.8 33.3 129.3 35.0 0.98
HDL-cholesterol (mg/dL) 49.2 13.4 42.9 8.5 0.23
Triglycerides (mg/dL) 115.8 71.3 93.6 33.7 0.30
1Standard deviation; 2Difference between groups were tested with t-Student unpaired test at 5% probability; 3BMI between 40 and 45 kg/m2; 4BMI
> 40 kg/m2; 5Body mass index; 6Waist circumference; 7Homeostasis Model Assessment; 8Quantitative Insulin Sensitivity Check Index. 
*p < 0,05.
Fig. 1.—Plasma glucose
(mg/dL) and serum insulin
(μU/mL) concentrations, in
fasting, 1 hour and 2 hours
postprandial in G1 and G2.
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increase in blood glucose and insulin one hour after
eating the test meal, followed by a fall two hours after,
but there was no significant difference (p > 0.05)
between groups (table II), however women with higher
BMI (G2) showed a higher peak of insulin secretion
one hour after eating the test meal.
Discussion
Obesity is considered a global epidemic and is asso-
ciated with the genesis of other chronic diseases.1
Studies relating adiposity and body fat distribution
with IR contribute to the understanding of the relation-
ship between obesity and other chronic diseases. More-
over, obesity is a complex disease of multifactorial
origin and among the etiological factors involved,
some genes are worth mentioning, such as the PPARγ2,
whose effect on the IS remains controversial, justifying
the genotyping of the women in this study.
In recent years, adipose tissue has become recog-
nized as one of the principal responsible for several
metabolic processes, with emphasis on energy balance
and glucose homeostasis.30,31 Among the genes and
transcription factors that regulate adipogenesis, the
nuclear receptor PPARγ has been detached.3,6,30 Further-
more, PPARγ ligands have shown excellent anti-
diabetic activity although most of these transcription
factors are found in adipose tissue and not in muscle.30,32
The presence of genetic variant may alter its function,
therefore, only carriers of the wild-type homozygous
genotype were selected (Pro12Pro), making it possible
to analyze the influence of adiposity on insulinemia
and glucemia in morbidly obese women, excluding the
possible influence of genotype on adiposity and IS.
The influence of adiposity in blood glucose and
insulin and, consequently, in response to insulin, is
already well established in literature.31,33,34,35 However,
there are few studies that control the possible influence
of genes and diet in the variables studied. In the present
study, the usual dietary intake did not differ between
groups, excluding the possibility of the influence of
habitual diet in the results.
Obesity is a major risk factor for the development of
IR33, the reason why the assessment of blood glucose
and insulin levels was carried out according to BMI. As
expected, G1 had lower body weight, BMI and WC,
compared to G2.
The visceral adiposity is strongly associated with
IR.1 In the present study, both groups had excess
visceral adiposity29, however, it was higher in G2. G2
also showed slightly altered fasting glucose19 and this
change was more frequent in this group. G1 and G2
showed average values of fasting insulin, above 9
µU/mL, indicating a state of hyperinsulinaemia
according to Sánchez-Margalet et al.20 Additionally,
both groups had IR, according Geloneze et al.22 In
contrast, when evaluating the IS, G1 showed normal
value, but G2 had low SI. Thus, in spite of all women
presenting morbid obesity, similar usual dietary intake
and the same genotype for PPARγ2, the results suggest
important metabolic differences with the increase of
BMI and visceral adiposity.
PUFA is a natural ligant of the PPARγ2, then we eval-
uated the glucose and insulin concentrations on period
postprandial after ingestion of this nutrient. We used a
breakfast with about 15% of the TEE of this type of fat. In
both groups, there was an increase in blood glucose and
insulin one hour after eating the test meal, followed by
fall two hours afterwards (fig. 1), despite the reduction in
IS typically detected in women with morbid obesity.
We also observed that after eating the meal, the
groups showed normal values of postprandial glucose
(< 140 mg/dL).19 G2 had a higher insulin secretion peak
1 hour after meal intake, compared to G1 (fig. 1), and
IS below the reference value.
There is little information about the type of PUFA that
is more potent for activating the PPARγ, furthermore the
vast majority of studies did not specify the type of PUFA
used. In few researches, different types of PUFA were
tested simultaneously.8,36 However, this study empha-
sizes the importance of controlling habitual dietary intake
and the PPARγ2 genotype, since the gene-environment
interactions are associated with the genesis of obesity and
other chronic diseases related to IR. 
It is important to emphasize that the differences
between the groups have great clinical and physiolog-
ical significance in view of the importance of IR in the
genesis of metabolic complications related to obesity.
Conclusions
It is possible to suggest that the body mass and the
distribution of adiposity may have influenced in
glycemia, whereas all women had the same genotype for
PPARγ2, beyond the similarity observed in usual dietary
intake between groups and of the same meal offered.
There was an increased risk for metabolic complica-
tions with the rise of body mass, although the volun-
teers had the same classification of obesity according
to BMI. The increased risk may be associated with
increased visceral adiposity, which is reflected in a
higher frequency of hyperglycemia and lower IS.
Studies with other genes, concerning the expression
of these with environmental factors, as well researches
involving individuals with different genotypes for
PPARγ2, are necessary to clarify other issues related to
the etiology, prevention and treatment of obesity,
emphasizing changes in environmental factors particu-
larly dietary factors.
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